Rutanen J, Rissanen T T, Kivelä A, Vajanto I, Ylä-Herttuala S
A.I. Virtanen Institute, University of Kuopio and Kuopio University Hospital, PO Box 1627, FIN-70211, Kuopio, Finland.
Curr Cardiol Rep. 2001 Jan;3(1):29-36. doi: 10.1007/s11886-001-0007-z.
Despite significant advances in prevention, coronary artery disease remains the leading cause of death in the Western world. Surgical bypass and angioplasty are the primary interventional therapies but they are limited by the problems of restenosis and graft occlusions. Natural response to vascular occlusion involves the formation of collateral vessels that bypass obstructions, but they are often inefficient in relieving ischemia. Vascular gene transfer offers a promising new approach to solve these problems. Its potential has been shown in animal models and in first human trials using vascular endothelial growth factor, fibroblast growth factor, and E2F cell-cycle transcription factor decoy. However, further basic research on gene transfer vectors, gene delivery techniques, and identification of effective treatment genes is needed to improve the efficacy and safety of human vascular gene therapy.
尽管在预防方面取得了重大进展,但冠状动脉疾病仍然是西方世界的主要死因。外科搭桥术和血管成形术是主要的介入治疗方法,但它们受到再狭窄和移植物闭塞问题的限制。对血管闭塞的自然反应涉及形成绕过阻塞的侧支血管,但它们在缓解缺血方面往往效率低下。血管基因转移为解决这些问题提供了一种有前景的新方法。其潜力已在动物模型以及使用血管内皮生长因子、成纤维细胞生长因子和E2F细胞周期转录因子诱饵的首次人体试验中得到证明。然而,需要对基因转移载体、基因递送技术以及有效治疗基因的鉴定进行进一步的基础研究,以提高人类血管基因治疗的疗效和安全性。